All In Biotech

NDA 213227 · Curium

Detectnet

Copper Cu-64 Dotatate · Intravenous · Radioactive Diagnostic Agent

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Dec 22, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Sep 3, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

8

2 Phase 3, 4 recruiting

FAERS reports

54

5 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 31, 2025.

Detectnet is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients. Detectnet is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients. ( 1 )

Mechanism: Copper Cu 64 dotatate binds to somatostatin receptors with highest affinity for subtype 2 receptors (SSTR2). It binds to cells that express somatostatin receptors including malignant neuroendocrine cells, which overexpress SSTR2 receptors. Copper Cu 64 is a positron (β + ) emitting radionuclide with an emission yield that allows positron emission tomography (PET) imaging.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 3, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterReviewLabel
1 products under this application
  • DETECTNET · COPPER CU-64 DOTATATE 4mL (1mCi/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Copper Cu-64 Dotatate" as an intervention, any sponsor and status, largest first.

All 8 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea22
  • flushing13
  • chest discomfort8
  • radioisotope scan abnormal7
  • palpitations6
  • abdominal pain5
  • chest pain4
  • drug ineffective4
  • incorrect drug administration rate4
  • vomiting4
  • dyspnoea3
  • hypersensitivity3

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20211
20221
20241
202540
202611

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Curium

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.